# Cadre Holdings, Inc.: overview CDRE · NYSE · CIK 1860543 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cdre.md) · [Financials](/companies/cdre/financials.md) · [Filings](/companies/cdre/filings.md) · [Insiders](/companies/cdre/insiders.md) Latest reported revenue: [$207.1m](/filings/0001104659-26-091151.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-091151). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [109](/filings/0001104659-25-106299.md) | [176 d](/filings/0001104659-26-025862.md) | [130](/filings/0001104659-26-058670.md) | [157](/filings/0001104659-26-091151.md) | [156](/filings/0001104659-25-106299.md) | [167 d](/filings/0001104659-26-025862.md) | [155](/filings/0001104659-26-058670.md) | [207](/filings/0001104659-26-091151.md) | | Gross margin | % | [36.6%](/filings/0001104659-25-106299.md) | [43.9% d](/filings/0001104659-26-025862.md) | [43.1%](/filings/0001104659-26-058670.md) | [40.9%](/filings/0001104659-26-091151.md) | [42.7%](/filings/0001104659-25-106299.md) | [43.4% d](/filings/0001104659-26-025862.md) | [38.7%](/filings/0001104659-26-058670.md) | [42.1%](/filings/0001104659-26-091151.md) | | Operating margin | % | [5.0%](/filings/0001104659-25-106299.md) | [16.7% d](/filings/0001104659-26-025862.md) | [10.4%](/filings/0001104659-26-058670.md) | [9.3%](/filings/0001104659-26-091151.md) | [12.0%](/filings/0001104659-25-106299.md) | [12.2% d](/filings/0001104659-26-025862.md) | [4.8%](/filings/0001104659-26-058670.md) | [10.8%](/filings/0001104659-26-091151.md) | | Net margin | % | [3.3%](/filings/0001104659-25-106299.md) | [7.4% d](/filings/0001104659-26-025862.md) | [7.1%](/filings/0001104659-26-091151.md) | [7.8%](/filings/0001104659-26-091151.md) | [7.0%](/filings/0001104659-25-106299.md) | [7.0% d](/filings/0001104659-26-025862.md) | [1.3%](/filings/0001104659-26-091151.md) | [5.5%](/filings/0001104659-26-091151.md) | | Diluted EPS | $ per share | [0.09](/filings/0001104659-25-106299.md) | not reported | [0.23](/filings/0001104659-26-058670.md) | [0.30](/filings/0001104659-26-091151.md) | [0.27](/filings/0001104659-25-106299.md) | not reported | [0.05](/filings/0001104659-26-058670.md) | [0.26](/filings/0001104659-26-091151.md) | | Free cash flow | $m | [(6.2) d](/filings/0001104659-25-106299.md) | [22.4 d](/filings/0001104659-26-025862.md) | [16.1](/filings/0001104659-26-058670.md) | [1.2 d](/filings/0001104659-26-091151.md) | [21.6 d](/filings/0001104659-25-106299.md) | [18.0 d](/filings/0001104659-26-025862.md) | [19.8](/filings/0001104659-26-058670.md) | [18.7 d](/filings/0001104659-26-091151.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [427](/filings/0001558370-24-002995.md) | [458](/filings/0001558370-25-002711.md) | [483](/filings/0001104659-26-025862.md) | [568](/filings/0001104659-26-025862.md) | [610](/filings/0001104659-26-025862.md) | | Gross margin | % | [39.9%](/filings/0001558370-24-002995.md) | [38.4%](/filings/0001558370-25-002711.md) | [41.6%](/filings/0001104659-26-025862.md) | [41.1%](/filings/0001104659-26-025862.md) | [42.5%](/filings/0001104659-26-025862.md) | | Operating margin | % | [12.1%](/filings/0001558370-24-002995.md) | [3.7%](/filings/0001558370-25-002711.md) | [11.7%](/filings/0001104659-26-025862.md) | [11.8%](/filings/0001104659-26-025862.md) | [11.0%](/filings/0001104659-26-025862.md) | | Net margin | % | [3.0%](/filings/0001558370-24-002995.md) | [1.3%](/filings/0001558370-25-002711.md) | [8.0%](/filings/0001104659-26-025862.md) | [6.4%](/filings/0001104659-26-025862.md) | [7.2%](/filings/0001104659-26-025862.md) | | Diluted EPS | $ per share | [0.44](/filings/0001558370-24-002995.md) | [0.16](/filings/0001558370-25-002711.md) | [1.02](/filings/0001104659-26-025862.md) | [0.90](/filings/0001104659-26-025862.md) | [1.02](/filings/0001104659-26-025862.md) | | Free cash flow | $m | [37.3](/filings/0001558370-24-002995.md) | [41.9](/filings/0001558370-25-002711.md) | [66.5](/filings/0001104659-26-025862.md) | [26.1](/filings/0001104659-26-025862.md) | [56.8](/filings/0001104659-26-025862.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cdre/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $83.7m | 2,936,878 | | Added +310,495 | | [Greenhouse Funds LLLP](/funds/1626220.md) | 2026-06-30 | $81.8m | 2,868,664 | | Added +286 | | [REINHART PARTNERS, LLC.](/funds/1080298.md) | 2026-06-30 | $78.1m | 2,738,373 | | Added +500,476 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $70.6m | 2,475,623 | | Reduced −843,573 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $55.6m | 1,949,734 | | Added +553,411 | | [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $46.3m | 1,622,466 | | Added +361,660 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $37.8m | 1,324,254 | | Added +76,805 | | [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $34.4m | 1,205,237 | | Added +32,880 | | [WYNNEFIELD CAPITAL INC](/funds/1251567.md) | 2026-06-30 | $34.4m | 1,205,000 | | Added +55,000 | | [Select Equity Group, L.P.](/funds/1592643.md) | 2026-06-30 | $33.7m | 1,181,921 | | Added +433,423 | ## Recent filings [All 406 filings](/companies/cdre/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 19:47 ET | [SCHEDULE 13D/A](/filings/0001104659-26-112476.md) | Ownership report, active investor, amended | 0001104659-26-112476 | | 2026-08-07 | 16:15 ET | [8-K/A](/filings/0001104659-26-092721.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092721 | | 2026-08-05 | 16:28 ET | [10-Q](/filings/0001104659-26-091151.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091151 | | 2026-08-05 | 16:25 ET | [8-K](/filings/0001104659-26-091143.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091143 | | 2026-07-29 | 16:15 ET | [8-K](/filings/0001104659-26-088148.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-088148 | | 2026-06-18 | 16:20 ET | [SCHEDULE 13D/A](/filings/0001104659-26-075751.md) | Ownership report, active investor, amended | 0001104659-26-075751 | | 2026-06-03 | 16:15 ET | [8-K](/filings/0001104659-26-070114.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001104659-26-070114 | | 2026-05-11 | 16:18 ET | [10-Q](/filings/0001104659-26-058670.md) | Quarterly report, period 2026-03-31 | 0001104659-26-058670 | | 2026-05-11 | 16:15 ET | [8-K](/filings/0001104659-26-058660.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-058660 | | 2026-04-24 | 08:30 ET | [DEF 14A](/filings/0001104659-26-048191.md) | Proxy statement, period 2026-05-29 | 0001104659-26-048191 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-025862.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/80b83356-7492-456a-b16b-2860b4897466) ## About the filer - CIK: 1860543 - Tickers: CDRE - Exchange: NYSE - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.